These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 24852919

  • 1. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 2. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E.
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 May 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 5. MiR-126: a novel route for natalizumab action?
    Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RL.
    Mult Scler; 2014 Sep 17; 20(10):1363-70. PubMed ID: 24598267
    [Abstract] [Full Text] [Related]

  • 6. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 17; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 7. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr 17; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 9. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb 15; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 10. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 15; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 15; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 15; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 13. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Oct 15; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 14. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr 15; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun 15; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

  • 16. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M, Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.
    Ann Neurol; 2017 Aug 15; 82(2):186-195. PubMed ID: 28681388
    [Abstract] [Full Text] [Related]

  • 17. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 15; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 18. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.
    Ann Neurol; 2015 Mar 15; 77(3):447-57. PubMed ID: 25581547
    [Abstract] [Full Text] [Related]

  • 19. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 15; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 20. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
    Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.
    Neurology; 2013 Sep 03; 81(10):865-71. PubMed ID: 23925765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.